In 2021 our group has pushed forward in the laboratory three main areas of research with the corresponding financial support and intellectual protection of the results: (i) use of radiogenomics and artificial intelligence to accurately discriminate between indolent and aggressive prostate cancer (PCa); (ii) study of new strategies to improve PCa diagnosis and management of BRCA-2 carriers (both from a clinical and molecular perspective); (iii) study of key mitotic regulators with a relevant role in resistance to hormone therapy and their potential as new therapeutic targets for treating the most aggressive tumors (with a focus on kinases and co-regulators, kinesins and ubiquitin ligases). We have generated models of primary cultures ex vivo and studied the mechanisms of progression and resistance to therapy. We have enlarged our collection of PCa liquid biopsies and tissues and provided with some of these samples to Joaquin Mateo's group at VHIO for collaborative PDXs collection.

Group Leader
Joan Morote Robles, Anna Santamaria Margalef

Researchers
Olga Méndez, Jacques Planas, Mercè Cuadras, Ana Celma, Lucas Regis, Inés de Torres, Maria Eugenia Semidey

PhD Students
Letícia Suárez, Marta Barber

Lab Technicians
David Ruiz

11

PUBLICATIONS

43

IMPACT FACTOR

3.89

AVERAGE IMPACT FACTOR

SELECTED ARTICLES

Olivan M#, Garcia M, Suarez L, Guiu M, Gros L, Méndez O, Rigau M, Reventos J, Segura MF, de Torres I, Planas J, de la Cruz X, Gomis RR, Morote J, Rodriguez-Barrueco R*, Santamaria A*#. (*co-last authors. #co-corresponding authors)
Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples.
Cancers (Basel). 2021 Dec 9;13(24)
DOI: 10.3390/cancers13246202
IF: 6.639

Masanas M, Masia N, Suarez-Cabrera L, Olivan M, Soriano A, Majem B, Devis-Jauregui L, Burgos-Panadero R, Jimenez C, Rodriguez-Sodupe P, Boloix A, Toledano I, Guillen G, Navarro A, Llobet-Navas D, Villanueva A, Sanchez de Toledo J, Roma J, Noguera R, Moreno L, Krauss R, Gallego S, Santamaria A*#, Segura MF*#. (*co-last authors, #co-corresponding authors)
The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models.
Clin Transl Med. 2021 Oct;11(10):e533
DOI: 10.1002/ctm2.533
IF: 11.492

Morote J*, Diaz F, Celma A, Planas J, Trilla E. (*corresponding author)
Behavior of SelectMDx and Prostate-specific Antigen Density in the Challenging Scenario of Prostate Imaging-Reporting and Data System Category 3 Lesions.
Eur Urol. 2021 Sep 30. pii: S0302-2838(21)02043-1
DOI: 10.1016/j.eururo.2021.09.019
IF: 20.096

Morote J*, Celma A, Planas J.(*corresponding author)
Are Multiparametric Magnetic Resonance Imaging and Guided Biopsies Needed in Men with Normal Digital Rectal Examination and Prostatic-specific Antigen >20 ng/ml?.
Eur Urol Oncol. 2021 Apr;4(2):334-335
DOI: 10.1016/j.euo.2021.02.004
IF: 7.479

Bradbury M, Borras E, Perez-Benavente A, Gil-Moreno A, Santamaria A*#, Sabido E*#. (*co-last authors, #co-corresponding authors)
Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review.
Cancers (Basel). 2021 Apr 25;13(9).
DOI: 10.3390/cancers13092067
IF: 6.639

Nuevos enfoques terapéuticos para el cáncer de próstata hormono-refractario basados en la quinesina KIF11 (PI17/02248).
Principal Investigator: Juan Morote
Agency: Instituto de Salud Carlos III
Funding: 100,000 €
Period: 2018-2020 (prolonged until June 2022)

SalivOmiX: Prova basada en la detecció de miRNAs en saliva per el diagnòstic precoç del càncer d’ovari (2019PROD00087).
Principal Investigator: Anna Santamaria Margalef
Agency: Agencia de Gestió d’Ajuts Universitaris i de Recerca-Modalitat Producte
Funding: 100,000 €
Period: June 2020- December 2021

Radiogenomics for the prediction of prostate cancer aggressiveness through artificial intelligence (PI20/01666).
Principal Investigator: Juan Morote
Agency: Instituto de Salud Carlos III
Funding: 151,250 €
Period: 2021-2023

Red Federada de Inteligencia Artificial para acelerar la Investigación Sanitaria (MIA.2021.M02.0005).
Principal Investigator: Anna Santamaria Margalef
Agency: Ministerio de Asuntos Económicos y Transformación Digital
Funding: 987,624 €
Period: 2021-2024

Nuevas estrategias para la mejora del diagnóstico y el manejo terapéutico de los portadores de mutaciones en BRCA2 (PI21/00977).
Principal Investigator: Anna Santamaria Margalef
Agency: Instituto de Salud Carlos III
Funding: 159,720 €
Period: 2022-2024

INHIBITOR OF MAP KINASE INTERACTING SERINE/THREONINE KINASE 1 (MNK1) AND MAP KINASE INTERACTING SERINE/THREONINE KINASE 2 (MNK2), CANCER THERAPY METHODS AND THERAPEUTIC COMBINATIONS
Priority Number: PCT/EP2020/069459 (WO2021005183)
Priority Date: 09/07/2020
Applicants: 47% VHIR/ 50% IQS /3% CIBERONC

Oncology

Research Areas